Densitas highlights study in Breast Cancer Research

By staff writers
February 21, 2018

Medical software developer Densitas is directing attention to a recent review that validated the clinical use of its automated breast-density measurement software to help stratify patients based on their risk for breast cancer.

The findings were published online February 5 in Breast Cancer Research.

Researchers from the University of Manchester in the U.K. reviewed five different methods for assessing breast density in 366 women participating in the Predicting Risk of Cancer at Screening (PROCAS) study. They found that both the Densitas software and the VolparaDensity algorithm (Volpara Solutions) could be used practically in breast cancer risk models due to the strong association of these density measurements with the risk of breast cancer.

Visual and semiautomated density assessments also show strong relationships with breast cancer risk, but the researchers judged these approaches to be impractical in population-based screening, Densitas said.

The company also said that several scientific and poster presentations at ECR 2018 in March will further confirm the clinical validation of its breast density software.

Densitas deploys breast density software throughout Canada
Medical software developer Densitas is rolling out its breast density software at clinics and hospitals throughout Canada.
Densitas touts breast density clinical research
Medical software developer Densitas is highlighting research presented at a workshop this week that it says demonstrates the value of its automated breast...
Densitas accepted into JLABS @ Toronto
Medical device firm Densitas was accepted at Johnson & Johnson Innovation's newest JLABS facility, JLABS @ Toronto
Densitas highlights breast density research at ECR
Medical device firm Densitas is highlighting two research studies using its breast density assessment software that were presented at this week's ECR...
Densitas receives CE Mark, Canadian clearance
Medical device firm Densitas has received the CE Mark from the European Commission and a medical device license from Health Canada for its DM-Density...

Copyright © 2018

Last Updated hh 2/22/2018 3:40:04 PM